Dr. Andrew Peter Dalovisio, MD

Dr. Dalovisio practices at Ochsner Medical Center - New Orleans in New Orleans, Louisiana, part of Ochsner Health System.

Dr. Dalovisio's NPI, 1144458704, was assigned on June 22, 2009. Dr. Dalovisio graduated from LSU Health Shreveport School of Medicine in 2009. Dr. Dalovisio's Louisiana license number on file is MD.207733.

Dr. Dalovisio's primary practice is Ochsner Medical Center - New Orleans, at 1516 Jefferson Hwy, New Orleans, LA 70121 in Jefferson Parish. The practice phone is (504) 842-3000.

Dr. Dalovisio's primary practice is Ochsner Medical Center - New Orleans in New Orleans, Louisiana, part of Ochsner Health System. Dr. Dalovisio is also affiliated with Baton Rouge General - Bluebonnet. The medical group on file is Ochsner Health. Dmand AI also links Dr. Dalovisio to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dalovisio practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dalovisio's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dalovisio is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dalovisio's licenses on file in 3 states: Louisiana, Alabama and Illinois.

Dmand AI lists anemia, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, fluid and electrolyte imbalances, immune deficiency disease and lung cancer among the conditions Dr. Dalovisio treats.

CMS data shows 1,162 Medicare services from Dr. Dalovisio across 8 procedure codes in 2024, for 264 Medicare patients. Medicare paid $80,277 for them.

CMS counts 264 Medicare patients who saw Dr. Dalovisio in 2024. The largest group is 65 to 74, with 127 patients. 74% of them have high blood pressure, and 63% have high cholesterol. 10% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dalovisio's median patient age at 70, with 49% women.

In 2024, Dr. Dalovisio wrote 2,821 Medicare Part D claims for 281 patients. 79% of them were for generic drugs. CMS names the drug for 2,450 of them, across 61 drugs with 11 or more claims each, at $12,338,743 in total drug cost. In 2023, CMS named 1,154 claims across 39 drugs.

Dr. Dalovisio accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dalovisio as offering telehealth.

Dmand AI links 7 papers to Dr. Dalovisio, published from 2014 to 2023. 2021 was the busiest year, with 2. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Cytarabine. Dr. Dalovisio's most frequent co-authors are Bhavana Bhatnagar, DO, Vijaya Raj Bhatt, MD and Dong Chen, MD, MS, PhD.

Dmand AI links Dr. Dalovisio to 5 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Burkitt Lymphoma. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 218 general payments to Dr. Dalovisio from 34 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Janssen Pharmaceuticals, Inc paid the most, $81,192. It also lists 21 research payments totaling $14,750 from 2017 to 2023.

Dr. Dalovisio graduated from LSU Health Shreveport School of Medicine in 2009.

Dr. Dalovisio is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.